Highlights Newsletter 2

This newsletter presents you the following key sessions:

1. Podcast with prof. Thomas Powles about the EV 301 trial: Phase III study of enfortumab vedotin versus
    chemotherapy in pre-treated locally advanced or metastatic urothelial carcinoma

2. Adding apalutamide to abiraterone acetate significantly delays the time to radiographic progression in
    patients with chemotherapy-naïve metastatic castration-resistant prostate cancer

3. Cabozantinib prolongs progression-free survival compared to sunitinib in metastatic papillary renal cell
    carcinoma

4. Biomarker analysis of metastatic castration-resistant prostate cancer patients who received ipatasertib
    plus abiraterone in the phase III IPATential150 trial

5. Stereotactic ablative body radiotherapy in combination with pembrolizumab shows efficacy in first-line
    for oligometastatic clear cell renal cell carcinoma